Industrialization of mAb production technology: The bioprocessing industry at a crossroads

 Abstract

Manufacturing processes for therapeutic monoclonal antibodies (mAbs) have evolved tremendously since the first licensed mAb product (OKT3) in 1986. The rapid growth in product demand for mAbs triggered parallel efforts to increase production capacity through construction of large bulk manufacturing plants as well as improvements in cell culture processes to raise product titers. This combination has led to an excess of manufacturing capacity, and together with improvements in conventional purification technologies, promises nearly unlimited production capacity in the foreseeable future. The increase in titers has also led to a marked reduction in production costs, which could then become a relatively small fraction of sales price for future products which are sold at prices at or near current levels. The reduction of capacity and cost pressures for current state-of-the-art bulk production processes may shift the focus of process development efforts and have important implications for both plant design and product development strategies for both biopharmaceutical and contract manufacturing companies.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
443 - 452
doi
10.4161/mabs.1.5.9448
Type
Review
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Industrialization of mAb production technology: The bioprocessing industry at a crossroads